LAVA Reports Second Quarter 2024 Financial Results and Business Update

UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody^® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate highlights.

Read more at globenewswire.com